Diamonds and Dogs


Mylan (MYL) finally has good news. After warning shareholders in August not to expect FDA approval for their multiple sclerosis treatment Copaxone, the FDA did in fact give Mylan approval driving the stock up 17% back to levels not seen since warning shareholders. I guess Mylan warned shareholders for no reason after all.

What's good news for Mylan was bad news for Teva Pharma (TEVA). The Israeli based drug company dropped 14% not far from its 52 week low as their $4 billion MS drug will face serious competition. JPMorgan analysts said Teva now faces full generic competition for Copaxone nine to 12 months earlier than expected. Teva has already been hurting due to weak generics prices in the United States and high debt levels.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.